I hesitate to bring this up but does anyone else find the
I hesitate to bring this up but does anyone else find the trial numbers suspicious?
Looking at them, I come to them with the conviction that I stated in msg 81679 - "Make no mistake - all recipients of Leronlimab benefited to some degree, even the ones too far gone to survive!" Not all of the trial patients were in the ICU because of Cytokine Storm but I know that Leronlimab shut down RANTES in everyone who got it! By some metric, Leronlimab helped everyone!
So why aren't we seeing the results we were expecting to see in these CD12 numbers? I'm not talking about primary and secondary endpoints and p values. I was expecting to see the result we saw from the first uses of Leronlimab with Seethamraju, Lang, Agresti and Reknor. Sure SOC has gotten better but NEWS type scores, Ordinal Scale numbers should have been better, much better in my opinion.
We had some large improvement by some individuals so of course the Ordinal Scale numbers would go up but if the numbers of all patients who got Leronlimab went up, we should see these number much higher. What happened to individual patients is lost in the average totals reported in the 8K report.
If something suspicious was going on, it would have shown itself in the individual cases where, after injection with Leronlimab, there was no patient improvement at all. We may not have used the metrics in the trial to show this but that result would have been there. Blood tests would have been nice but just the clinical outcomes should have been obvious.
This issue really worries me because if something funny went on with the CD12 trials, it could go funny with this CD16 trial. What are the checks and balances? Are we totally sure that those who were supposed to get Leronlimab really did get Leronlimab?
Can we compare the Ordinal (NEWS) type scores of those who got Leronlimab thru OLE and eINDs with those in the CD12 trial? Can we insist on blood tests after Leronlimab administration in the CD16 trial? We can't afford any screw-ups!
3
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Black Friday Heat Kicks Off Early at Aosom All the seasoned shoppers out there smell a deal from a mile away, and Aosom isn't taking any chances by launching their Black Friday bash smack dab on November 2nd. This isn’t just any sale, it’s shaping up to be their most gigantic festival of discounts yet. Across Europe and North America, folks are rubbing their hands...
Continue Reading
Trading Mayhem: Pre-Market Vibes Ever put your ear to the ground on the NYSE floor and felt that buzz of untamed optimism clashing with skepticism? Today it's all about connections, from the data-driven to the familial. Imagine Stellantis (NYSE: STLA) is making a play, aligning with Amperity in an ambitious attempt to make customer interactions feel more personal. Now,...
Continue Reading
Tackling the Age-Old Heating Puzzle Ah, the charm of an older home—from the creaky floors to the vintage architecture, it's something else. But, let's face it, keeping these houses warm can feel like patching up an old ship. Our man Reid Sittler, HVAC aficionado from Massillon, Ohio, shares some no-nonsense insights on how to stop your precious heat from slipping...
Continue Reading
Comedy's Heavyweights Hit the Road for 2027 Tour Kicking off in Milwaukee on February 5, 2027, comedy gets a new spotlight as BMN Entertainment launches the much-anticipated return of the 'We Them One's' Comedy Tour. This isn't your run-of-the-mill comedy gig, folks. We're talking about headlining act Mike Epps, comedy’s sharp shooter and stage powerhouse, teaming up...
Continue Reading
A Golden Opportunity in Uncertain Times Monetary Metals just pulled a rabbit outta the hat with this $38 million gold bond. That’s tripling the size from their 2024 offering. Normally, I'm skeptical about flashy bond numbers, but there's a glint of genius here. In a world teetering on the brink of financial chaos, investors are itching for something solid. And gold?...
Continue Reading
Ah, the thrill of the pre-IPO buzz. Vantage has thrown its hat into the ring with a pre-IPO CFD offering, giving stock jockeys like you and me a chance to express our bullish or bearish convictions before a company goes public. The question is: does this open new doors for the sharp-eyed investor, or are we just adding another layer of risk onto an already wild ride?...
Continue Reading
Oil's November Gambit: OPEC+ and U.S. Dynamics November's here, and boy, it's shaping up to be a wild one for the oil market. OPEC+ decided to stick with their oil production targets for December, leaving the supply faucets unchanged. This group, including big players like Saudi Arabia and Russia, met virtually and chose to hit the brakes on any changes just yet. With the...
Continue Reading
Tampa Steps into the Global Art Scene Get this, Tampa is gearing up for its slice of the global art pie. Come October 2026, the Tampa Convention Center will transform into a bustling hub of creativity and culture. With over 300 artists slated to pour in from every corner of the globe, this isn't just any old art fair—it's Art Fair Tampa, and it's promising to be a...
Continue Reading
Industrial Automation Surge: A New Era Dawns There's no denying it, folks: the gears are turning at a breakneck pace in the industrial automation world. We've got our eyes set on a staggering climb from $266.7 billion in 2026 to a jaw-dropping $410.3 billion by 2031. That's a 9% annual growth rate that's got investors salivating. Robotics and AI: Leading the Charge Look...
Continue Reading
Uniquely Coastal Celebrations in Myrtle Beach Forget the snow, friends. Picture this: you’re swapping out cozy firesides for ocean breezes this holiday season. Down in Myrtle Beach, the holidays have a bit of a coastal twist. From the vibrant Boardwalk along the oceanfront to the historic charm of riverside Conway, this area is lighting up its 14 different communities...
Continue Reading
Top 5 Most Recently Viewed Articles
Marsh McLennan Announces Quarterly Cash Dividend Marsh McLennan (NYSE: MMC) has announced its latest quarterly cash dividend, set at $0.815 per share for its outstanding common stock. This dividend highlights the company's solid financial health and will be payable to all stockholders on record as of a designated upcoming date. As a leading global professional services...
Continue Reading
A2P and P2A Messaging Market Growth Forecast The A2P and P2A messaging market is witnessing tremendous growth owing to the escalation of mobile device usage and the increasing demand for effective communication between businesses and their clientele. As organizations strive to boost customer engagement and streamline their operations, the adoption of automated messaging...
Continue Reading
Rapid7 Launches Vector Command Advanced In today's cyber landscape, organizations are increasingly under pressure to demonstrate the effectiveness of their security measures. To address this need, Rapid7, Inc. (NASDAQ: RPD), a pioneering force in threat detection and exposure management, has introduced Vector Command Advanced. This innovative offering enhances their...
Continue Reading
Fortrea Holdings Inc. Faces Investigation The law firm of Kirby McInerney LLP has initiated an investigation into Fortrea Holdings Inc. (NASDAQ: FTRE) on behalf of concerned investors. This inquiry aims to determine if the company and its executives have violated federal securities laws or engaged in questionable business practices that may have adversely impacted...
Continue Reading
TDb Split Corp. Announces Monthly Dividend for Shareholders In a recent announcement, TDb Split Corp. has confirmed its monthly distribution for shareholders. For each Class A share, the dividend is set at $0.05000, which translates to an annualized figure of $0.60. Meanwhile, holders of Priority Equity shares will receive $0.05833, or $0.700 on an annual basis. These...
Continue Reading